Get our lovely INSIGHT 2019 conference news


Email address
First Name
Last Name
Interested in InSight 2019
Cart
<We_can_help/>

What are you looking for?

<Good_things_happen/> Welcome to Conference

Evaluating the therapeutic potential of hallucinogens in rat models of alcohol addiction

Oral Presentation

Worldwide more than 2 billion people consume alcohol. Nearly 60 million EU citizens engage in harmful drinking and 23 million Europeans are suffering from alcohol addiction. Approved pharmacological treatments for alcoholism are limited in their effectiveness, and new drugs that can be translated into the clinic are warranted. In the last decade, there was considerable enthusiasm that advances in the field of neuroscience would soon translate into mechanistically novel alcohol addiction therapies. However, several new mechanisms that appeared to hold great promise based on preclinical data failed to translate to the human condition. We have created a working group (BMBF funded Project: Psi-Alc) with partners in Switzerland, Italy and France aiming to improve the reliability of preclinical academic research and produce meaningful and translatable results for subsequent cost-intensive Phase II/III testing in alcohol-addicted patients.

There is preliminary evidence for the safety and efficacy of classical psychedelics, such as LSD and psilocybin, in the treatment of alcohol addiction (e.g. Bogenschutz et al.; Grob et al.); however, large-scale randomized controlled trials are missing. We are using a unique rat models for alcohol addiction and have implemented a novel concept of randomized multi-center preclinical phase II testing in laboratory animals. Prior to time-intensive discussions with regulatory bodies, dose determination and finally cost-intensive phase II clinical testing for psilocybin in alcoholics, our Psi-Alc working group is currently assessing the effectiveness and safety of psilocybin in rats for treating alcohol addiction, including a step-wise translation into alcoholic patients.

We will be able to present pilot data on alcohol relapse behavior measured by the alcohol deprivation effect in male and female rats. Final data will guide us to build up a robust preclinical data set for a promising translation to the patient.

Speaker

Date

September 7th 2019

Time

14:45-15:15

Location

Room: Rudolf Virchow
tickets
Marcus Meinhardt
M.Sc.

Marcus Meinhardt

University of Applied Sciences Mannheim more about the speaker

Related Events

Direct within-subject comparison of the acute subjective and autonomic effects of LSD, MDMA, and amphetamine in healthy subjects

Acute effects of a prototypic hallucinogen, entactogen, and stimulant have never been compared directly within healthy subjects. Therefore, we assessed and compared responses to the hallucinogen lysergic acid diethylamide (LSD), the entactogen 3,4-methylenedioxymethamphetamine (MDMA), the stimulant d-amphetamine, and placebo in humans in a controlled laboratory setting. We used a double-blind, placebo-controlled, cross-over study design in 28 healthy volunteers (14 females, 14 males) to investigate the acute subjective and autonomic responses to 0.1 mg LSD, 125 mg MDMA, 40 mg d-amphetamine, […]

more details

Evaluating the therapeutic potential of hallucinogens in rat models of alcohol addiction

Worldwide more than 2 billion people consume alcohol. Nearly 60 million EU citizens engage in harmful drinking and 23 million Europeans are suffering from alcohol addiction. Approved pharmacological treatments for alcoholism are limited in their effectiveness, and new drugs that can be translated into the clinic are warranted. In the last decade, there was considerable enthusiasm that advances in the field of neuroscience would soon translate into mechanistically novel alcohol addiction therapies. However, several new mechanisms that appeared to hold […]

more details

Phenomenology of the ketamine experience, reports from Ketamine Assisted Psychotherapy (KAP)

Ketamine is unique from the known and loved phenethylamines, tryptamines, and ergolines (all Schedule 1 drugs in the U.S. and highly controlled), which tend exert their effects by interacting with serotonin, dopamine, and/or norepinephrine receptors. Ketamine is classified as a dissociative anesthetic and is listed as a Schedule III drug in the United States. It has a novel mechanism of action as a N-methyl-D-aspartate (NMDA) receptor antagonist. In addition, its effects can be quite different from the more typical hallucinogens/psychedelics/entheogens […]

more details

Conference tickets

With your ticket you will have access to the whole conference - with keynotes, panels, round tables, posters and daylight social events. We will ask for a small extra fee for the Friday evening social program. The pre-conference workshops have to be booked separately and each workshop needs an individual ticket. By clicking on "Book now" below you also have the option to buy your workshop tickets.

*Reduced fees apply to students, cooperation partners as well as unemployed and retired individuals who have a monthly net income below 840,- €. Proof of status will be required.

Early bird

until 14 April 2019

  • Standard €170
  • Reduced €80*
  • MIND members Standard €100
  • MIND members Reduced €50

Regular

after 14 April 2019

  • Standard €250
  • Reduced €150*
  • MIND members Standard €180
  • MIND members Reduced €90

Philanthropist

 

  • Donate €600 or more
  • Invite a friend/colleague to be your VIP guest at the event

Get our lovely INSIGHT 2019 conference news


Email address
First Name
Last Name